Key result
Clopidogrel monotherapy is linked to similar MACCE but ~64% less major bleeding than DAPT post-CABG.
Why the study?
The optimal antiplatelet strategy for secondary prevention in patients with chronic coronary syndrome undergoing CABG remains uncertain.
Does clopidogrel monotherapy reduce major adverse cardiovascular and cerebrovascular events or major bleeding compared to dual antiplatelet therapy in patients with chronic coronary syndrome following coronary artery bypass grafting?
Cohort (n=9,046)
Yes
Does clopidogrel monotherapy reduce major adverse cardiovascular and cerebrovascular events or major bleeding compared to dual antiplatelet therapy in patients with chronic coronary syndrome following coronary artery bypass grafting?
In patients with chronic coronary syndrome following CABG, clopidogrel monotherapy may be a safer alternative to DAPT, offering similar ischemic protection with significantly less major bleeding.
Answers are grounded in this paper and cite their sources.
Should not yet change to clopidogrel monotherapy post-CABG in CCS; leaves open optimal strategy pending randomized trials.
The optimal antiplatelet strategy for secondary prevention in patients with chronic coronary syndrome (CCS) undergoing coronary artery bypass grafting (CABG) remains uncertain.Using the Korean National Health Insurance Service database, we analyzed 9,046 patients with CCS who underwent CABG between 2010 and 2020.Compared with dual antiplatelet therapy (DAPT), clopidogrel monotherapy was associated with a similar incidence of major adverse cardiovascular and cerebrovascular events and a significantly lower risk of major bleeding.These findings suggest that clopidogrel monotherapy may represent a clinically meaningful alternative to DAPT in this population.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a cohort in Chronic coronary syndrome (CCS) following coronary artery bypass grafting (CABG) (n=9,046). Clopidogrel monotherapy vs. Dual antiplatelet therapy (DAPT) was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) (HR 1.05, 95% CI 0.85-1.29). Clopidogrel monotherapy showed similar MACCE incidence and lower major bleeding risk compared to DAPT in patients with chronic coronary syndrome after CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: